AB 2760: Prescription drugs: prescribers: naloxone hydrochloride and other FDA-approved drugs.
- Session Year: 2017-2018
- House: Assembly
- Latest Version Date: 2018-09-10
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when certain conditions are present and to provide education on overdose prevention and the use of naloxone hydrochloride or another drug to the patient and specified others, except as specified. The bill would subject a prescriber to referral to the board charged with regulating his or her license for the imposition of administrative sanctions, as that board deems appropriate, for violating those provisions.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when certain conditions are present and to provide education on overdose prevention and the use of naloxone hydrochloride or another drug to the patient and specified others, except as specified. The bill would subject a prescriber to referral to the board charged with regulating his or her license for the imposition of administrative sanctions, as that board deems appropriate, for violating those provisions.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when certain conditions are present and to provide education on overdose prevention and the use of naloxone hydrochloride or another drug to the patient and specified others. others, except as specified. The bill would subject a prescriber to referral to the board charged with regulating his or her license for the imposition of administrative sanctions, as that board deems appropriate, for violating those provisions.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to offer a prescription for naloxone hydrochloride or another opioid antagonist drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when certain conditions are present and to provide education on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist drug to the patient and specified others. The bill would make a violation of the bills provisions unprofessional conduct and would subject the prescriber to discipline by a prescriber to referral to the board charged with regulating his or her license. license for the imposition of administrative sanctions, as that board deems appropriate, for violating those provisions.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to prescribe offer a prescription for naloxone hydrochloride for patients or another opioid antagonist to a patient when certain conditions are present and to provide specified education on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist to those patients and their households. the patient and specified others. The bill would make a violation of the bills provisions unprofessional conduct and would subject the prescriber to discipline by the board charged with regulating his or her license.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to prescribe naloxone hydrochloride for patients when certain conditions are present and to provide specified education to those patients and their household. households. The bill would make a violation of the bills provisions unprofessional conduct and would subject the prescriber to discipline by the board charged with regulating his or her license.
Existing law provides for the regulation of health care practitioners and requires prescription drugs to be ordered and dispensed in accordance with the Pharmacy Law. Existing law authorizes a pharmacist to furnish naloxone hydrochloride in accordance with standardized procedures or protocols developed by both the California State Board of Pharmacy and the Medical Board of California.
This bill would require a prescriber, as defined, to prescribe naloxone hydrochloride for patients when certain conditions are present and to provide specified education to those patients and their household. The bill would make a violation of the bills provisions unprofessional conduct and would subject the prescriber to discipline by the board charged with regulating his or her license.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.(a)Notwithstanding any other law, a prescriber shall do the following:
(1)Offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present:
(A)The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
(B)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(C)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(2)Consistent with the existing standard of care, provide education to patients receiving a prescription under paragraph (1) on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression.
(3)Consistent with the existing standard of care, provide education on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to one or more persons designated by the patient, or, for a patient who is a minor, to the minors parent or guardian.
(b)This section does not apply to a prescriber when prescribing to an inmate or a youth under the jurisdiction of the Department of Corrections and Rehabilitation or the Division of Juvenile Justice within the Department of Corrections and Rehabilitation.
742.A prescriber who fails to offer a prescription, as required by paragraph (1) of subdivision (a) of Section 741, or fails to provide the education and use information required by paragraphs (2) and (3) of subdivision (a) of Section 741 shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescribers liability for the negligent failure to diagnose or treat a patient.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.(a)Notwithstanding any other law, a prescriber shall do the following:
(1)Offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present:
(A)The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
(B)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(C)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(2)Consistent with the existing standard of care, provide education to patients receiving a prescription under paragraph (1) on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression.
(3)Consistent with the existing standard of care, provide education on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to one or more persons designated by the patient, or, for a patient who is a minor, to the minors parent or guardian.
(b)This section does not apply to a prescriber when prescribing to an inmate or a youth under the jurisdiction of the Department of Corrections and Rehabilitation or the Division of Juvenile Justice within the Department of Corrections and Rehabilitation.
742.A prescriber who fails to offer a prescription, as required by paragraph (1) of subdivision (a) of Section 741, or fails to provide the education and use information required by paragraphs (2) and (3) of subdivision (a) of Section 741 shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescribers liability for the negligent failure to diagnose or treat a patient.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.(a)Notwithstanding any other law, a prescriber shall do the following:
(a)(1)Offer a prescription for naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present:
(1)(A)The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
(2)(B)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3)(C)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b)(2)Consistent with the existing standard of care, provide education to patients receiving a prescription under subdivision (a) paragraph (1) on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression.
(c)(3)Consistent with the existing standard of care, provide education on overdose prevention and the use of naloxone hydrochloride or another drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to one or more persons designated by the patient, or, for a patient who is a minor, to the minors parent or guardian.
(b)This section does not apply to a prescriber when prescribing to an inmate or a youth under the jurisdiction of the Department of Corrections and Rehabilitation or the Division of Juvenile Justice within the Department of Corrections and Rehabilitation.
742.A prescriber who fails to offer a prescription, as required by paragraph (1) of subdivision (a) of Section 741, or fails to provide the education and use information required by subdivisions (b) and (c) paragraphs (2) and (3) of subdivision (a) of Section 741 shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescribers liability for the negligent failure to diagnose or treat a patient.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.Notwithstanding any other law, a prescriber shall do the following:
(a)Offer a prescription for naloxone hydrochloride or another opioid antagonist drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to a patient when one or more of the following conditions are present:
(1)The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
(2)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b)Provide Consistent with the existing standard of care, provide education to patients receiving a prescription under subdivision (a) on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist. drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression.
(c)Provide Consistent with the existing standard of care, provide education on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist drug approved by the United States Food and Drug Administration for the complete or partial reversal of opioid depression to one or more persons designated by the patient, or, for a patient who is a minor, to the minors parent or guardian.
742.A violation of this article constitutes unprofessional conduct and grounds for disciplinary action by the prescribers licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that boards prescribers.742.A prescriber who fails to offer a prescription, as required by subdivision (a) of Section 741, or fails to provide the education and use information required by subdivisions (b) and (c) of Section 741 shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescribers liability for the negligent failure to diagnose or treat a patient.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.Notwithstanding any other law, a prescriber shall do the following:
(a)Prescribe Offer a prescription for naloxone hydrochloride for or another opioid antagonist to a patient when one or more of the following conditions are present:
(1)The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
(2)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b)Provide education to patients receiving a prescription under subdivision (a) and their households on overdose prevention and the use of naloxone hydrochloride. hydrochloride or another opioid antagonist.
(c)Provide education on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist to one or more persons designated by the patient, or, for a patient who is a minor, to the minors parent or guardian.
742.A violation of this article constitutes unprofessional conduct and grounds for disciplinary action by the prescribers licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that boards prescribers.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.(a)Notwithstanding any other law, a prescriber shall do the following:
(a)Prescribe naloxone hydrochloride for a patient when one or more of the following conditions are present:
(1)The prescription dosage for a the patient is between 50 and 100 90 or more morphine milligram equivalents of an opioid medication per day.
(2)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b)Provide education to patients receiving a prescription under subdivision (a) and their households on overdose prevention and the use of naloxone hydrochloride.
742.A violation of this article constitutes unprofessional conduct and grounds for disciplinary action by the prescribers licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that boards prescribers.
The Legislature finds and declares all of the following:
(a)Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b)After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c)Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d)Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e)Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f)Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g)Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2.Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:10.7Opioid Medication740.For purposes of this article, prescriber means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741.(a)Notwithstanding any other law, a prescriber shall do the following:
(a)Prescribe naloxone hydrochloride for a patient when one or more of the following conditions are present:
(1)The prescription dosage for a patient is between 50 and 100 morphine milligram equivalents of an opioid medication per day.
(2)An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3)The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b)Provide education to patients receiving a prescription under subdivision (a) and their households on overdose prevention and the use of naloxone hydrochloride.
742.A violation of this article constitutes unprofessional conduct and grounds for disciplinary action by the prescribers licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that boards prescribers.
|
Date
|
Status
|
|---|---|
| Sep 10, 2018 | Chaptered by Secretary of State - Chapter 324, Statutes of 2018. |
| Sep 10, 2018 | Approved by the Governor. |
| Aug 29, 2018 | Enrolled and presented to the Governor at 4 p.m. |
| Aug 23, 2018 | Senate amendments concurred in. To Engrossing and Enrolling. |
| Aug 20, 2018 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after August 22 pursuant to Assembly Rule 77. |
| Aug 20, 2018 | Read third time. Passed. Ordered to the Assembly. |
| Aug 16, 2018 | Read second time. Ordered to third reading. |
| Aug 15, 2018 | Read third time and amended. Ordered to second reading. |
| Aug 7, 2018 | Read second time. Ordered to third reading. |
| Aug 6, 2018 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Jun 20, 2018 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 19, 2018 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 18). |
| May 30, 2018 | Referred to Com. on B., P. & E.D. |
| May 22, 2018 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 21, 2018 | Read third time. Passed. Ordered to the Senate. |
| May 17, 2018 | Read second time. Ordered to third reading. |
| May 16, 2018 | From committee: Do pass. (Ayes 17. Noes 0.) (May 16). |
| Apr 23, 2018 | Re-referred to Com. on APPR. |
| Apr 19, 2018 | Read second time and amended. |
| Apr 18, 2018 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 15. Noes 0.) (April 17). |
| Apr 10, 2018 | From committee: Do pass and re-refer to Com. on HEALTH. (Ayes 14. Noes 1.) (April 10). Re-referred to Com. on HEALTH. |
| Apr 4, 2018 | Re-referred to Com. on B. & P. |
| Apr 3, 2018 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Mar 8, 2018 | Referred to Coms. on B. & P. and HEALTH. |
| Feb 17, 2018 | From printer. May be heard in committee March 19. |
| Feb 16, 2018 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 23, 2018 | AB 2760 WOOD Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 20, 2018 | Assembly 3rd Reading AB2760 Wood By Hernandez | Senate Floor |
Passed |
|
| Jun 18, 2018 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| May 21, 2018 | AB 2760 WOOD Assembly Third Reading | Assembly Floor |
Passed |
|
| May 16, 2018 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 17, 2018 | Do pass as amended, and be re-referred to the Committee on [Appropriations] with recommendation: To Consent Calendar | Assembly Standing Committee on Health |
Passed |
|
| Apr 10, 2018 | Do pass and be re-referred to the Committee on [Health] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2760
Author:(Wood)
As Amended Ver:August 15, 2018
Majority vote
ASSEMBLY: | 70-0 | (May 21, 2018) | SENATE: | 38-0 | (August 20, 2018) |
Original Committee Reference: B. & P.
SUMMARY: Requires a prescriber to offer a prescription for naloxone hydrochloride or another drug federally approved for the complete or partial reversal of opioid depression for patients when certain conditions are present and to provide specified education to those patients and provide education about how these drugs may be used to prevent an overdose.
The Senate amendments broaden the type of prescription that must be offered from "opioid antagonist" to any drug federally approved for the complete or partial reversal of opioid depression and specify that failing to offer a prescription or provide education is subject only to board discipline through imposition of administrative sanctions and not enforceable through a private right of action. The amendments also exempt a prescriber when prescribing to an inmate or a youth under the jurisdiction of the Department of Corrections and Rehabilitation or the Division of Juvenile Justice within the Department of Corrections and Rehabilitation.
EXISTING LAW:
- Allows only a physician, dentist, podiatrist, veterinarian, naturopathic doctor, registered nurse, certified nurse-midwife, optometrist, or out-of-state prescriber to write or issue a prescription. (Health and Safety Code (HSC) Section 11150)
- States that a prescription for a controlled substance shall only be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his or her professional practice, and that the responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. (HSC Section 11153)
- Prohibits medical professionals from prescribing, administering, or dispensing a controlled substance to an addict, as defined. (HSC Section 11156)
- Prohibits any person from obtaining or attempting to obtain a prescription for controlled substances, by fraud, deceit, misrepresentation, subterfuge, or the concealment of a material fact. (HSC Section 11173)
- Authorizes a pharmacist to furnish naloxone hydrochloride (without a prescription) in accordance with standardized procedures or protocols developed and approved by the Board of Pharmacy and the Medical Board. (Business and Professions Code (BPC) Section 4052.01)
- Authorizes a licensed health care provider who is authorized by law to prescribe an opioid antagonist to prescribe and subsequently dispense or distribute an opioid antagonist to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of an opioid-related overdose. (Civil Code Section 1714.22)
FISCAL EFFECT: According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, negligible state costs.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author:
While efforts aimed at stemming the opioid crisis appear to be making some inroads, the sheer number and potential for ever increasing numbers requires pro-active action on the part of the legislature. Requiring the co-prescribing of naloxone for those at high-risk places an immediate deterrent into the hands of those directly impacted or into the hands of their family and caregivers. It is a tool that can immediately save lives and hopefully provide an opportunity for discussion of treatment for individuals suffering from substance use disorder.
Background. Naloxone hydrochloride and other opioid antagonists. Naloxone hydrochloride (brand name Narcan) is an opioid antagonist. This means that naloxone acts blocks the effects of opioids on the central nervous system, stopping the effects of an opioid overdose such as suppressed breathing. Naloxone can be administered through an intravenous injection, through an intermuscular injection, or via a nasal spray. Naloxone was approved by the federal Food and Drug Administration for the treatment of opioid overdose in 1971 and is available as a generic medication. Because naloxone is simple to administer and does not pose significant risk to the patient, it can be used by lay people with minimal instruction. Current law allows a prescriber to prescribe naloxone to an individual at risk of an opioid overdose or to a family member, friend, or other person in a position to assist an individual who is at risk of an opioid overdose. Current law also allows a pharmacist to dispense naloxone, without a prescription, provided standard protocols are followed.
Benzodiazepines and opioid risks. Benzodiazepines are a class of drugs used to treat anxiety, insomnia, agitation, seizures, muscle spasms, and alcohol withdrawal. When taken in combination with drugs that suppress central nervous system depressants, such as opioids, the risk of fatal overdose increases. According to the Food and Drug Administration, there has been an increase in the level of co-prescribing of opioids and benzodiazepines and this has led to an increase in adverse outcomes.
American Medical Association Opioid Task Force. In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing naloxone with opioid pain medications when it is clinically appropriate to do so.
The Task Force indicated that physicians should consider:
- Whether the patient is on a high opioid dose,
- Whether the patient is on a benzodiazepine prescription,
- Whether the patient has a history of substance abuse disorder,
- Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose,
- Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose,
- Whether the patient may be in a position to aid someone at risk of an overdose.
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0004217
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 2760
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 6/18/18
AYES: Hill, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
NO VOTE RECORDED: Fuller
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 70-0, 5/21/18 - See last page for vote
DIGEST:
This bill requires a prescriber to prescribe naloxone hydrochloride (NH) or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of opioid depression for patients when certain conditions are present and to provide education to patients.
Senate Floor Amendments of 8/15/18 exempt health care practitioners, pharmacists, or pharmacies providing health care services to an inmate, individual on parole, or youth under the jurisdiction of the Department of Corrections and Rehabilitation from the provisions of the bill.
Existing law:
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian or naturopathic doctor (ND). (BPC § 4059)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), certified nurse midwife (CNM) (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), nurse practitioner (NP) (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or physician assistant acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Permits a pharmacist to furnish NH in accordance with standardized procedures or protocols developed and approved by both the Board of Pharmacy and Medical Board of California, in consultation with the California Society of Addiction Medicine, the California Pharmacists Association, and other appropriate entities. (Id.)
- Authorizes a pharmacy to furnish naloxone or another opioid antagonist to a school district, county office of education (COE), or charter school if all the naloxone or another opioid antagonist is furnished exclusively for use at a school district school-site, COE school-site, or charter school, and a physician and surgeon provides a written order that specifies the quantity of naloxone or another opioid antagonist to be furnished. (BPC § 4119.08)
- Authorizes a licensed health care provider to prescribe and dispense NH to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of an opioid related overdose. (Civil Code § 1714.22)
- Authorizes a licensed health care provider to issue standing orders for the administration of NH to a person at risk of an opioid-related overdose, a family member, friend, or other person in a position to assist a person experiencing or reasonably suspected of experiencing an overdose. (Id.)
- Requires a person who is prescribed or possesses NH pursuant to a standing order to receive training provided by an opioid overdose prevention and treatment training program operated by a local health jurisdiction or that is registered by a local health jurisdiction that provides, at a minimum, training in (Id.):
- The causes of an opiate overdose.
- Mouth to mouth resuscitation.
- How to contact appropriate emergency medical services.
- How to administer NH.
This bill:
- Requires a prescriber, defined as a person licensed, certified, registered, or otherwise subject to regulation who is authorized to prescribe prescription drugs, to offer a prescription for NH or another or another drug approved by the FDA under certain conditions.
- Requires a prescriber to provide education to patients on overdose prevention and the use of NH or another or another drug approved by the FDA and provide education on overdose prevention and the use of NH or another or another drug approved by the FDA to one or more persons designated by the patient, or, for a patient who is a minor, to the minor’s parent or guardian.
- Specifies that a violation of these provisions shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescriber’s liability for the negligent failure to diagnose or treat a patient.
- Exempts health care practitioners, pharmacists, or pharmacies providing health care services to an inmate, individual on parole, or youth under the jurisdiction of the Department of Corrections and Rehabilitation from the provisions of the bill.
Background
Prescription drug deaths. Prescription opioids continue to be involved in more overdose deaths than any other drug. The National Institute on Drug Abuse reports that more than 1,700 young adults died from prescription drug overdose in 2014, a four-fold increase from 1999, nearly five persons per day. According to the Centers for Disease Control and Prevention (CDC), overdose deaths involving prescription opioids have quadrupled since 1999. CDC found that from 1999 to 2015, more than 183,000 people died in the U.S. from overdoses related to prescription opioids. CDC notes that the most common drugs involved in prescription opioid overdose deaths are methadone, oxycodone and hydrocodone. According to the CDC, among those who died from prescription opioid overdose between 1999 and 2014, overdose rates were highest among people aged 25 to 54, overdose rates were higher among non-Hispanic whites and American Indian or Alaskan Natives, compared to non-Hispanic blacks and Hispanics and men were more likely to die from overdose, but the mortality gap between men and women is closing.
Naloxone Hydrochloride. NH, better known as Narcan, is an opioid antidote that can reverse a drug overdose. NH reverses depression of the central nervous system and respiratory systems that have shut down during an overdose. NH is commonly used when a person excessively uses morphine, oxycodone, methadone, or illegal substances such as heroin. NH is meant to sustain breathing for 30-90 minutes, during which time emergency medical services should be sought for the patient. The drug is non-narcotic, does not produce intoxication, and has no potential for addiction or abuse. NH also only causes pharmacological effects if there are opioids in someone’s body. If NH is administered to someone who is not overdosing, no adverse effects will happen.
According to the U.S. Surgeon General’s Advisory on Naloxone, expanding the awareness and availability of NH is a key part of the public health response to the opioid epidemic. The Advisory states that research shows that when NH and overdose education are available to community members, overdose deaths decrease in those communities. The CDC’s Guideline for Prescribing Opioids for Chronic Pain advises health care providers to consider offering NH to individuals when factors that increase risk for overdose or concurrent benzodiazepine use are present.
In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing NH with opioid pain medications when it is clinically appropriate to do so. The Task Force indicated that physicians should consider:
- Whether the patient is on a high opioid dose.
- Whether the patient is on a benzodiazepine prescription.
- Whether the patient has a history of substance abuse disorder.
- Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose.
- Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose.
- Whether the patient may be in a position to aid someone at risk of an overdose.
Seventeen states and the District of Columbia have enacted laws expanding access to NH.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
A New Path
California Association of Code Enforcement Officers
California Chronic Care Coalition
California College and University Police Chiefs Association
California Council of Community Behavioral Agencies
California Hepatitis C Task Force
California Narcotic Officers Association
California Pharmacists Association
Congress of California Seniors
County Behavioral Health Directors Association
County Health Executives Association of California
Drug Policy Alliance
Emergency Medical Services Medical Directors Association of California
Los Angeles County Professional Peace Officers Association
McKesson Corporation
Medical Board of California
National Health Law Program
Western Center on Law & Poverty
3 individuals
OPPOSITION: (Verified 8/15/18)
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Medical Association
ARGUMENTS IN SUPPORT: California Council of Community Behavioral Agencies, California Hepatitis C Task Force, A New Path, and County Health Executives Association of California note that 2,000 Californians died, in 2016, as a result of a drug related death. Public health experts have called for expanding access to prescribing naloxone with opioid medication. National Health Law Program, Western Center on Law & Poverty, California Chronic Care Coalition, Drug Policy Alliance, Congress of California Seniors write in support and note that AB 2760 will ensure that those who are prescribed opioids and are at risk of an overdose and receive the overdose reversing medication. Emergency Medical Services Medical Directors Association of California, California Pharmacists Association, write in support and note with the ever increasing opioid crisis, prescribing Naloxone is an important strategy to combat overdoses. Congress of California Seniors writes in support, “Data from the U.S. Center for Disease Control shows an alarming rise in the number of opioid deaths among those ages 65-74 with 16 deaths in 1999 increasing to 680 in 2014, up 4,150 percent. …AB 2760 will provide seniors and those who care for them with critical tools to help combat opioid deaths among any age group.” The Medical Board of California writes in support, “this bill will increase at-risk patients’ access to naloxone and other opioid antagonists, which will further the Board’s mission of consumer protection.” McKesson Corporation writes in support, “McKesson believes pharmacists in every state should be permitted to dispense and be reimbursed for opioid overdose antidotes with a prescription…we continue to support increased access to opioids reversal medication.”
ARGUMENTS IN OPPOSITION: California Chapter of the American College of Emergency Physicians and the California Medical Association write in opposition and note that physicians and emergency physicians should be able to determine the appropriate treatment plan for their patients.
California Academy of Family Physicians (CAFP) opposes this bill unless it is amended, noting that concerns remain with the requirement that a prescription for “rescue medication” must be offered, thereby legislating the practice of medicine. CAFP notes that NH does not need a prescription. CAFP is requesting that the Author replace the requirement to offer a prescription with language to inform patients about the availability of NH. The organization also suggests ensuring the education requirements in the bill “are the responsibility of whomever is physically dispensing the [NH]” and asks the Author to remove the language stating that it is unprofessional conduct for noncompliance of any provision of this bill.
ASSEMBLY FLOOR: 70-0, 5/21/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cunningham, Dahle, Daly, Flora, Fong, Frazier, Friedman, Gallagher, Gipson, Gloria, Gonzalez Fletcher, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Quirk-Silva, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Chávez, Cooper, Eggman, Cristina Garcia, Eduardo Garcia, Gray, Kiley, Muratsuchi
8/18/18 13:59:02
**** END ****
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB |
THIRD READING
Bill No: AB 2760
:
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 8-0, 6/18/18
AYES: Hill, Allen, Dodd, Galgiani, Glazer, Hernandez, Pan, Wilk
NO VOTE RECORDED: Fuller
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 70-0, 5/21/18 - See last page for vote
DIGEST:
This bill requires a prescriber to prescribe naloxone hydrochloride (NH) or another drug approved by the United States Food and Drug Administration (FDA) for the complete or partial reversal of opioid depression for patients when certain conditions are present and to provide education to patients.
Existing law:
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian or naturopathic doctor (ND). (BPC § 4059)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), certified nurse midwife (CNM) (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), nurse practitioner (NP) (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or physician assistant acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Permits a pharmacist to furnish NH in accordance with standardized procedures or protocols developed and approved by both the Board of Pharmacy and Medical Board of California, in consultation with the California Society of Addiction Medicine, the California Pharmacists Association, and other appropriate entities. (Id.)
- Authorizes a pharmacy to furnish naloxone or another opioid antagonist to a school district, county office of education (COE), or charter school if all the naloxone or another opioid antagonist is furnished exclusively for use at a school district school-site, COE school-site, or charter school, and a physician and surgeon provides a written order that specifies the quantity of naloxone or another opioid antagonist to be furnished. (BPC § 4119.08)
- Authorizes a licensed health care provider to prescribe and dispense NH to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of an opioid related overdose. (Civil Code § 1714.22)
- Authorizes a licensed health care provider to issue standing orders for the administration of NH to a person at risk of an opioid-related overdose, a family member, friend, or other person in a position to assist a person experiencing or reasonably suspected of experiencing an overdose. (Id.)
- Requires a person who is prescribed or possesses NH pursuant to a standing order to receive training provided by an opioid overdose prevention and treatment training program operated by a local health jurisdiction or that is registered by a local health jurisdiction that provides, at a minimum, training in (Id.):
- The causes of an opiate overdose.
- Mouth to mouth resuscitation.
- How to contact appropriate emergency medical services.
- How to administer NH.
- Does not require a person who is prescribed NH directly from a licensed prescriber to receive training from an opioid prevention and treatment training program. (Id.)
This bill:
- States findings and declarations about the impacts of abuse and misuse of opioids.
- Requires a prescriber, defined as a person licensed, certified, registered, or otherwise subject to regulation who is authorized to prescribe prescription drugs, to offer a prescription for NH or another or another drug approved by the FDA under certain conditions.
- Requires a prescriber to provide education to patients on overdose prevention and the use of NH or another or another drug approved by the FDA and provide education on overdose prevention and the use of NH or another or another drug approved by the FDA to one or more persons designated by the patient, or, for a patient who is a minor, to the minor’s parent or guardian.
- Specifies that a violation of these provisions shall be referred to the appropriate licensing board solely for the imposition of administrative sanctions deemed appropriate by that board. This section does not create a private right of action against a prescriber, and does not limit a prescriber’s liability for the negligent failure to diagnose or treat a patient.
Background
Prescription drug deaths. Prescription opioids continue to be involved in more overdose deaths than any other drug. The National Institute on Drug Abuse reports that more than 1,700 young adults died from prescription drug overdose in 2014, a four-fold increase from 1999, nearly five persons per day. According to the Centers for Disease Control and Prevention (CDC), overdose deaths involving prescription opioids have quadrupled since 1999. CDC found that from 1999 to 2015, more than 183,000 people died in the U.S. from overdoses related to prescription opioids. CDC notes that the most common drugs involved in prescription opioid overdose deaths are methadone, oxycodone and hydrocodone. According to the CDC, among those who died from prescription opioid overdose between 1999 and 2014, overdose rates were highest among people aged 25 to 54, overdose rates were higher among non-Hispanic whites and American Indian or Alaskan Natives, compared to non-Hispanic blacks and Hispanics and men were more likely to die from overdose, but the mortality gap between men and women is closing.
Naloxone Hydrochloride. NH, better known as Narcan, is an opioid antidote that can reverse a drug overdose. NH reverses depression of the central nervous system and respiratory systems that have shut down during an overdose. NH is commonly used when a person excessively uses morphine, oxycodone, methadone, or illegal substances such as heroin. NH is meant to sustain breathing for 30-90 minutes, during which time emergency medical services should be sought for the patient. The drug is non-narcotic, does not produce intoxication, and has no potential for addiction or abuse. NH also only causes pharmacological effects if there are opioids in someone’s body. If NH is administered to someone who is not overdosing, no adverse effects will happen.
NH is typically administered intramuscularly, which causes the drug to act within one minute and last up to 45 minutes. The emergency treatment works like the well-known EpiPen, an epinephrine auto-injector for serious allergic reactions, as it is injected into the muscle and does not require training, making it more user-friendly. NH may also be administered via intravenously, subcutaneous (under the skin), or intranasally. A typical injectable or nasal spray NH kit costs $15-$25 per dose.
According to the U.S. Surgeon General’s Advisory on Naloxone, expanding the awareness and availability of NH is a key part of the public health response to the opioid epidemic. The Advisory states that research shows that when NH and overdose education are available to community members, overdose deaths decrease in those communities. The CDC’s Guideline for Prescribing Opioids for Chronic Pain advises health care providers to consider offering NH to individuals when factors that increase risk for overdose or concurrent benzodiazepine use are present.
In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing NH with opioid pain medications when it is clinically appropriate to do so. The Task Force indicated that physicians should consider:
- Whether the patient is on a high opioid dose.
- Whether the patient is on a benzodiazepine prescription.
- Whether the patient has a history of substance abuse disorder.
- Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose.
- Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose.
- Whether the patient may be in a position to aid someone at risk of an overdose.
Seventeen states and the District of Columbia have enacted laws expanding access to NH.
FISCAL EFFECT: Appropriation: Fiscal Com.: Local:
A New Path
California Association of Code Enforcement Officers
California Chronic Care Coalition
California College and University Police Chiefs Association
California Council of Community Behavioral Agencies
California Hepatitis C Task Force
California Narcotic Officers Association
California Pharmacists Association
Congress of California Seniors
County Behavioral Health Directors Association
County Health Executives Association of California
Drug Policy Alliance
Emergency Medical Services Medical Directors Association of California
Los Angeles County Professional Peace Officers Association
McKesson Corporation
Medical Board of California
National Health Law Program
Western Center on Law & Poverty
3 individuals
California Academy of Family Physicians
California Chapter of the American College of Emergency Physicians
California Medical Association
ARGUMENTS IN SUPPORT: California Council of Community Behavioral Agencies, California Hepatitis C Task Force, A New Path, and County Health Executives Association of California note that 2,000 Californians died, in 2016, as a result of a drug related death. Public health experts have called for expanding access to prescribing naloxone with opioid medication. National Health Law Program, Western Center on Law & Poverty, California Chronic Care Coalition, Drug Policy Alliance, Congress of California Seniors write in support and note that AB 2760 will ensure that those who are prescribed opioids and are at risk of an overdose and receive the overdose reversing medication. Emergency Medical Services Medical Directors Association of California, California Pharmacists Association, write in support and note with the ever increasing opioid crisis, prescribing Naloxone is an important strategy to combat overdoses. Congress of California Seniors writes in support, “Data from the U.S. Center for Disease Control shows an alarming rise in the number of opioid deaths among those ages 65-74 with 16 deaths in 1999 increasing to 680 in 2014, up 4,150 percent. …AB 2760 will provide seniors and those who care for them with critical tools to help combat opioid deaths among any age group.” The Medical Board of California writes in support, “this bill will increase at-risk patients’ access to naloxone and other opioid antagonists, which will further the Board’s mission of consumer protection.” McKesson Corporation writes in support, “McKesson believes pharmacists in every state should be permitted to dispense and be reimbursed for opioid overdose antidotes with a prescription…we continue to support increased access to opioids reversal medication.”
ARGUMENTS IN OPPOSITION: California Chapter of the American College of Emergency Physicians and the California Medical Association write in opposition and note that physicians and emergency physicians should be able to determine the appropriate treatment plan for their patients.
California Academy of Family Physicians (CAFP) opposes this bill unless it is amended, noting that concerns remain with the requirement that a prescription for “rescue medication” must be offered, thereby legislating the practice of medicine. CAFP notes that NH does not need a prescription. CAFP is requesting that the Author replace the requirement to offer a prescription with language to inform patients about the availability of NH. The organization also suggests ensuring the education requirements in the bill “are the responsibility of whomever is physically dispensing the [NH]” and asks the Author to remove the language stating that it is unprofessional conduct for noncompliance of any provision of this bill.
ASSEMBLY FLOOR: 70-0, 5/21/18
AYES: Acosta, Aguiar-Curry, Travis Allen, Arambula, Baker, Berman, Bigelow, Bloom, Bonta, Brough, Burke, Caballero, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cunningham, Dahle, Daly, Flora, Fong, Frazier, Friedman, Gallagher, Gipson, Gloria, Gonzalez Fletcher, Grayson, Harper, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Nazarian, Obernolte, O'Donnell, Patterson, Quirk, Quirk-Silva, Reyes, Rodriguez, Rubio, Salas, Santiago, Steinorth, Mark Stone, Thurmond, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Chávez, Cooper, Eggman, Cristina Garcia, Eduardo Garcia, Gray, Kiley, Muratsuchi
8/8/18 16:00:36
**** END ****
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Jerry Hill, Chair
2017 - 2018 Regular
Bill No: Hearing Date: June 18, 2018
Author: | |||
Version: | April 19, 2018 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Sarah Mason | ||
Subject:
SUMMARY: Requires a prescriber to prescribe naloxone hydrochloride for patients when certain conditions are present and to provide education to patients.
Existing law:
- Establishes various practice acts in the Business and Professions Code (BPC) governed by various boards within the Department of Consumer Affairs (DCA) which provide for the licensing and regulation of health care professionals including: physicians and surgeons (under the Medical Practice Act), dentists (under the Dental Practice Act), veterinarians (under the Veterinary Medicine Practice Act); registered nurses, nurse practitioners (NP) and certified nurse-midwives (CNM) (under the Nursing Practice Act); physician assistants (PA) (under the Physician Assistant Practice Act); osteopathic physicians and surgeons (under the Osteopathic Medical Practice Act); naturopathic doctors (ND) (under the Naturopathic Doctors Act); optometrists (under the Optometry Practice Act); doctors of podiatric medicine (under the Podiatric Act) and; pharmacies, pharmacists and wholesalers of dangerous drugs or devices (under the Pharmacy Law). (Business and Professions Code (BPC) §§ 500 et seq.)
- Specifies certain requirements regarding the dispensing and furnishing of dangerous drugs and devices, and prohibits a person from furnishing any dangerous drug or device except upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian or ND. (BPC § 4059)
- Establishes the Uniform Controlled Substances Act which regulates controlled substances and defines an opiate as any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. (Health and Safety Code (HSC) § 11020)
- Classifies controlled substances into five schedules according to their danger and potential for abuse. (HSC §§ 11054-11058)
- Prohibits any person other than a physician, dentist, podiatrist, veterinarian, ND (according to certain supervision and protocol requirements), pharmacist (according to certain authorization and according to certain policies and procedures), CNM (if furnished or ordered incidentally to the provision of family planning services, routine health care or perinatal care, or care rendered consistent with the CNM’s practice; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified), NP (if it is consistent with a NP’s educational preparation or for which clinical competency has been established and maintained; occurs under physician and surgeon supervision; and is in accordance with standardized procedures or protocols as specified); a pharmacist or registered nurse or PA acting within the scope of an experimental health workforce project authorized by the Office of Statewide Health Planning and Development (HSC §§ 128125 et seq.); an optometrist licensed under the Optometry Practice Act, or an out-of-state prescriber acting in an emergency situation from writing or issuing a prescription for a controlled substance. (HSC § 11150)
- Permits a pharmacist to furnish NH in accordance with standardized procedures or protocols developed and approved by both the Board of Pharmacy and Medical Board of California, in consultation with the California Society of Addiction Medicine, the California Pharmacists Association, and other appropriate entities. (Id.)
- Authorizes a pharmacy to furnish naloxone or another opioid antagonist to a school district, county office of education (COE), or charter school if all the naloxone or another opioid antagonist is furnished exclusively for use at a school district school-site, COE school-site, or charter school, and a physician and surgeon provides a written order that specifies the quantity of naloxone or another opioid antagonist to be furnished. (BPC § 4119.08)
- Requires records regarding the acquisition and disposition of naloxone or another opioid antagonist furnished to be maintained by the school district, COE, or charter school for a period of three years from the date the records were created. Requires the school district, COE, or charter school to be responsible for monitoring the supply of naloxone or another opioid antagonist and ensuring the destruction of expired naloxone or another opioid antagonist. (Id.)
- Authorizes a licensed health care provider to prescribe and dispense NH to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of an opioid related overdose. (Civil Code (CIV) § 1714.22)
- Authorizes a licensed health care provider to issue standing orders for the administration of NH to a person at risk of an opioid-related overdose, a family member, friend, or other person in a position to assist a person experiencing or reasonably suspected of experiencing an overdose. (Id.)
- Requires a person who is prescribed or possesses NH pursuant to a standing order to receive training provided by an opioid overdose prevention and treatment training program operated by a local health jurisdiction or that is registered by a local health jurisdiction that provides, at a minimum, training in (Id.):
- The causes of an opiate overdose.
- Mouth to mouth resuscitation.
- How to contact appropriate emergency medical services.
- How to administer NH.
- Does not require a person who is prescribed NH directly from a licensed prescriber to receive training from an opioid prevention and treatment training program. (Id.)
This bill:
- States findings and declarations about the impacts of abuse and misuse of opioids.
- Requires a prescriber, defined as a person licensed, certified, registered, or otherwise subject to regulation who is authorized to prescribe prescription drugs, to offer a prescription for NH or another opioid antagonist to a patient when one or more of the following conditions are present:
- The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
- An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
- The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
- Requires a prescriber to provide education to patients on overdose prevention and the use of NH or another opioid antagonist and provide education on overdose prevention and the use of NH or another opioid antagonist to one or more persons designated by the patient, or, for a patient who is a minor, to the minor’s parent or guardian.
- States that a violation of these provisions constitutes unprofessional conduct and grounds for disciplinary action by the prescriber’s licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that board’s prescribers.
FISCAL EFFECT: This bill is keyed fiscal by Legislative Counsel. According to the Assembly Committee on Appropriations analysis dated May 16, 2018, this bill will result in uncertain potential costs to the Medi-Cal program, as Medi-Cal would likely incur higher costs to reimburse for additional NH or other opioid antagonists, which may be offset by fewer health care services related to overdose. The analysis notes that the bill will also result in ongoing enforcement costs to the Medical Board of California and the Board of Pharmacy’s costs will likely increase, but the extent of the increase is unknown.
COMMENTS:
- Purpose. The Author is the Sponsor of this bill. According to the Author, “California and the nation as a whole are experiencing an opioid epidemic. For the 24 month period July 2015 through July 2017, thousands of Californians lost their lives as a result of drug overdoses, a trend primarily driven by opioids including heroin and fentanyl.” The Author states that when administered quickly and appropriately, NH prevents drug overdose deaths. According to the Author, “currently, it is common practice for emergency rooms and emergency first responders to administer [NH] when encountering a drug overdose.” The Author states that this bill seeks to ensure that NH is also readily available and in the hands of individuals who are at high-risk for drug overdose and/or available to family and friends who may be with individuals when the overdose-increasing the likelihood of immediate administration and thereby saving lives. According to the Author, “co-prescribing naloxone to individuals who meet certain risk categories will help to stem the rising numbers of drug overdose deaths in California.”
- Prescription Drug Deaths. Prescription opioids continue to be involved in more overdose deaths than any other drug. The National Institute on Drug Abuse reports that more than 1,700 young adults died from prescription drug overdose in 2014, a 4-fold increase from 1999, nearly 5 persons per day. According to the Centers for Disease Control (CDC), overdose deaths involving prescription opioids have quadrupled since 1999. CDC found that from 1999 to 2015, more than 183,000 people died in the U.S. from overdoses related to prescription opioids. CDC notes that the most common drugs involved in prescription opioid overdose deaths are methadone, oxycodone and hydrocodone. According to the CDC, among those who died from prescription opioid overdose between 1999 and 2014, overdose rates were highest among people aged 25 to 54, overdose rates were higher among non-Hispanic whites and American Indian or Alaskan Natives, compared to non-Hispanic blacks and Hispanics and men were more likely to die from overdose, but the mortality gap between men and women is closing.
- Naloxone Hydrochloride. Naloxone Hydrochloride (NH), better known as Narcan, is an opioid antidote that can reverse a drug overdose. NH reverses depression of the central nervous system and respiratory systems that have shut down during an overdose. NH is commonly used when a person excessively uses morphine, oxycodone, methadone, or illegal substances such as heroin. NH is meant to sustain breathing for 30-90 minutes, during which time emergency medical services should be sought for the patient. The drug is non-narcotic, does not produce intoxication, and has no potential for addiction or abuse. NH also only causes pharmacological effects if there are opioids in someone’s body. If NH is administered to someone who is not overdosing, no adverse effects will happen.
NH is typically administered intramuscularly, which causes the drug to act within one minute and last up to 45 minutes. The emergency treatment works like the well-known EpiPen, an epinephrine auto-injector for serious allergic reactions, as it is injected into the muscle and does not require training, making it more user-friendly. NH may also be administered via intravenously, subcutaneous (under the skin), or intranasally. A typical injectable or nasal spray NH kit costs $15-$25 per dose.
According to the U.S. Surgeon General’s Advisory on Naloxone, expanding the awareness and availability of NH is a key part of the public health response to the opioid epidemic. The Advisory states that research shows that when NH and overdose education are available to community members, overdose deaths decrease in those communities. The Centers for Disease Control and Prevention’s Guideline for Prescribing Opioids for Chronic Pain advises health care providers to consider offering NH to individuals when factors that increase risk for overdose or concurrent benzodiazepine use are present.
In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing NH with opioid pain medications when it is clinically appropriate to do so. The Task Force indicated that physicians should consider:
- Whether the patient is on a high opioid dose.
- Whether the patient is on a benzodiazepine prescription.
- Whether the patient has a history of substance abuse disorder.
- Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose.
- Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose.
- Whether the patient may be in a position to aid someone at risk of an overdose.
Seventeen states and the District of Columbia have enacted laws expanding access to NH.
- Related Legislation This Year. AB 1963 (Waldron) requires the Department of Health Care Services to increase Medi-Cal provider reimbursement rates for opioid addiction treatment by an unspecified percentage of the corresponding average rates established in the 2017-18 fiscal year. Specifically, this bill specifies rate increases for "medication-assisted treatments, buprenorphine/naloxone combination treatment, methadone treatment, and naltrexone treatments provided by certified providers for opioid addiction." (Status: The bill was held under submission in the Assembly Committee on Appropriations.)
AB 1998 (Rodriguez) requires every healthcare practitioner authorized to prescribe Schedule II and Schedule III opioids to adopt a safe prescribing policy. (Status: The bill is also pending in this committee.)
AB 2256 (Santiago) authorizes a pharmacy, wholesaler, or manufacturer to provide NH or another opioid antagonist to law enforcement agencies, under specified conditions. (Status: This bill is pending in the Senate Committee on Appropriations.)
AB 2384 (Arambula) would require health care service plans that provide prescription drug benefits and maintains one or more drug formularies to include specified medication-assisted treatment prescription drugs approved by the United States Food and Drug Administration, including NH in at least one form of administration. (Status: This bill is pending in the Senate Committee on Health.)
- Prior Related Legislation. AB 1748 (Mayes, Chapter 557, Statutes of 2016) authorized school nurses and other trained personnel to use NH or another opioid antagonist to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an opioid overdose. This bill also authorized pharmacies to furnish NH without a prescription, to a school district, county office of education, or charter school.
AB 1535 (Bloom, Chapter 326, Statutes of 2014) authorized a pharmacist to furnish NH pursuant to standardized procedures and protocols developed and approved jointly by the Board of Pharmacy (BOP) and the Medical Board of California (MBC).
- Arguments in Support. California Council of Community Behavioral Agencies, California Hepatitis C Task Force, A New Path, and County Health Executives Association of California write in support and note that in 2016 2,000 Californian’s died as a result of a drug related death. Public health experts have called for expanding access to prescribing naloxone with opioid medication.
National Health Law Program, Western Center on Law & Poverty, California Chronic Care Coalition, Drug Policy Alliance, Congress of California Seniors write in support and note that AB 2760 will ensure that those who are prescribed opioids and are at risk of an overdose and receive the overdose reversing medication.
Emergency Medical Services Medical Directors Association of California, California Pharmacists Association, write in support and note with the ever increasing opioid crisis, prescribing Naloxone is an important strategy to combat overdoses.
Congress of California Seniors writes in support, “Data from the U.S. Center for Disease Control shows an alarming rise in the number of opioid deaths among those ages 65-74 with 16 deaths in 1999 increasing to 680 in 2014, up 4,150 percent. …AB 2760 will provide seniors and those who care for them with critical tools to help combat opioid deaths among any age group.”
The Medical Board of California writes in support, “this bill will increase at-risk patients’ access to naloxone and other opioid antagonists, which will further the Board’s mission of consumer protection.”
McKesson writes in support, “McKesson believes pharmacists in every state should be permitted to dispense and be reimbursed for opioid overdose antidotes with a prescription…we continue to support increased access to opioids reversal medication.”
- Arguments in Opposition. California Chapter of the American College of Emergency Physicians and the California Medical Association write in opposition and note that physicians and emergency physicians should be able to determine the appropriate treatment plan for their patients.
California Academy of Family Physicians (CAFP) opposes this bill unless it is amended, noting that concerns remain with the requirement that a prescription for “rescue medication” must be offered, thereby legislating the practice of medicine. CAFP notes that NH does not need a prescription. CAFP is requesting that the Author replace the requirement to offer a prescription with language to inform patients about the availability of NH. The organization also suggests ensuring the education requirements in the bill “are the responsibility of whomever is physically dispensing the [NH]” and asks the Author to remove the language stating that it is unprofessional conduct for noncompliance of any provision of this bill.
- Proposed Author’s Amendments. In response to concerns raised by opponents above and in order to further clarify the intent of the bill, the Author has proposed the following changes to the bill (as outlined in the mockup below):
- Include language specifying that the education provided to patients is consistent with existing standards of care.
- Clarify that another drug approved by the Food and Drug Administration for the complete or partial reversal of opioid depression may be prescribed to the patient populations this bill is targeting.
- Update language in the bill currently establishing unprofessional conduct for a violation to instead specify that a health care practitioner who fails to meet the electronic capability standards and who fails to e-prescribe shall be referred to the appropriate state professional licensing board solely for administrative sanctions, as deemed appropriate by that board. The changes specify that this section does not create a private right or action against a health care practitioner and does not limit a health care practitioner’s liability for the negligent failure to diagnose or treat a patient.
SUPPORT AND OPPOSITION:
Support:
A New Path
California Association of Code Enforcement Officers
California Chronic Care Coalition
California College and University Police Chiefs Association
California Council of Community Behavioral Agencies
California Hepatitis C Task Force
California Narcotic Officers Association
California Pharmacists Association
Congress of California Seniors
County Behavioral Health Directors Association
County Health Executives Association of California
Drug Policy Alliance
Emergency Medical Services Medical Directors Association of California
Los Angeles County Professional Peace Officers Association
McKesson Corporation
Medical Board of California
National Health Law Program
Western Center on Law & Poverty
3 individuals
Opposition:
California Chapter of the American College of Emergency Physicians
California Medical Association
California Academy of Family Physicians
-- END –
Mockup of AB 2760 as proposed to be amended
The people of the State of California do enact as follows:
SECTION 1. The Legislature finds and declares all of the following:
(a) Abuse and misuse of opioids is a serious problem that affects the health, social, and economic welfare of the state.
(b) After alcohol, prescription drugs are the most commonly abused substances by Americans over 12 years of age.
(c) Almost 2,000,000 people in the United States suffer from substance use disorders related to prescription opioid pain relievers.
(d) Nonmedical use of prescription opioid pain relievers can be particularly dangerous when the products are manipulated for snorting or injection or are combined with other drugs.
(e) Deaths involving prescription opioid pain relievers represent the largest proportion of drug overdose deaths, greater than the number of overdose deaths involving heroin or cocaine.
(f) Driven by the continued surge in drug deaths, life expectancy in the United States dropped for the second year in a row in 2016, resulting in the first consecutive decline in national life expectancy since 1963.
(g) Should 2017 also result in a decline in life expectancy as a result of drug deaths, it would be the first three-year period of consecutive life expectancy declines since World War I and the Spanish flu pandemic in 1918.
SEC. 2. Article 10.7 (commencing with Section 740) is added to Chapter 1 of Division 2 of the Business and Professions Code, to read:
Article 10.7 Opioid Medication
740. For purposes of this article, “prescriber” means a person licensed, certified, registered, or otherwise subject to regulation pursuant to this division, or an initiative act referred to in this division, who is authorized to prescribe prescription drugs.
741. Notwithstanding any other law, a prescriber shall do the following:
(a) Offer a prescription for naloxone hydrochloride or another opioid antagonist to a patient when one or more of the following conditions are present:
(1) The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day
(2) An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
(3) The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
(b) Consistent with the existing standard of care, pProvide education to patients receiving a prescription under subdivision (a) on overdose prevention and the use of naloxone hydrochloride or another another drug approved by the Food and Drug Administration for the complete or partial reversal of opioid depression. opioid antagonist.
(c) Consistent with the existing standard of care, pProvide education on overdose prevention and the use of naloxone hydrochloride or another drug approved by the Food and Drug Administration for the complete or partial reversal of opioid depression. opioid antagonist to one or more persons designated by the patient, or, for a patient who is a minor, to the minor’s parent or guardian.
742. A violation of this article constitutes unprofessional conduct and grounds for disciplinary action by the prescriber’s licensing board. Each licensing board established under this division, or under an initiative act referred to in this division, shall be charged with enforcing this article as it pertains to that board’s prescribers. A health care practitioner who fails to offer a co-prescripton of naloxone as required by subdivision 741(a) or provide the education and use information as required by subdivisions 741 (b) and (c) shall be referred to the appropriate state professional licensing board solely for administrative sanctions, as deemed appropriate by that board. This section does not create a private right or action against a health care practitioner. This section does not limit a health care practitioner’s liability for the negligent failure to diagnose or treat a paient.
ASSEMBLY THIRD READING
ATR Bill Id:AB 2760
Author:(Wood)
As Amended Ver:April 19, 2018
Majority vote
Committee | Votes | Ayes | Noes |
Business & Professions | 14-1 | Low, Brough, Arambula, Baker, Bloom, Chen, Chiu, Eggman, Gipson, Grayson, Holden, Irwin, Mullin, Ting | Cunningham |
Health | 15-0 | Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Rodriguez, Santiago, Thurmond, Waldron | |
Appropriations | 17-0 | Gonzalez Fletcher, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Eggman, Fong, Friedman, Gallagher, Eduardo Garcia, Nazarian, Obernolte, Quirk, Reyes |
SUMMARY: Requires a prescriber to offer a prescription for naloxone hydrochloride or another opioid antagonist for patients when certain conditions are present and to provide specified education to those patients. Specifically, this bill:
- Requires a prescriber to offer a prescription for naloxone hydrochloride or another opioid antagonist for a patient when one or more of the following conditions are present:
- The prescription dosage for the patient is over 90 morphine milligram equivalents of an opioid medication per day.
- An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
- The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
- Requires a prescriber to provide education to patients receiving a prescription under this bill on overdose prevention and the use of naloxone hydrochloride or another opioid antagonist.
- Makes a violation of this bill's provisions unprofessional conduct and grounds for disciplinary action by the prescriber's licensing board.
FISCAL EFFECT: According to the Assembly Appropriations Committee, uncertain potential costs to the Medi-Cal program and unknown ongoing enforcement costs to the Medical Board and Board of Pharmacy.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author, "while efforts aimed at stemming the opioid crisis appear to be making some inroads, the sheer number and potential for ever increasing numbers requires pro-active action on the part of the legislature. Requiring the co-prescribing of naloxone for those at high-risk places an immediate deterrent into the hands of those directly impacted or into the hands of their family and caregivers. It is a tool that can immediately save lives and hopefully provide an opportunity for discussion of treatment for individuals suffering from substance use disorder."
Background. Naloxone hydrochloride and other opioid antagonists. Naloxone hydrochloride (brand name Narcan) is an opioid antagonist. This means that naloxone acts blocks the effects of opioids on the central nervous system, stopping the effects of an opioid overdose such as suppressed breathing. Naloxone can be administered through an intravenous injection, through an intermuscular injection, or via a nasal spray. Naloxone was approved by the federal Food and Drug Administration for the treatment of opioid overdose in 1971 and is available as a generic medication. Because naloxone is simple to administer and does not pose significant risk to the patient, it can be used by lay people with minimal instruction. Current law allows a prescriber to prescribe naloxone to an individual at risk of an opioid overdose or to a family member, friend, or other person in a position to assist an individual who is at risk of an opioid overdose. Current law also allows a pharmacist to dispense naloxone, without a prescription, provided standard protocols are followed.
Benzodiazepines and opioid risks. Benzodiazepines are a class of drugs used to treat anxiety, insomnia, agitation, seizures, muscle spasms, and alcohol withdrawal. When taken in combination with drugs that suppress central nervous system depressants, such as opioids, the risk of fatal overdose increases. According to the Food and Drug Administration, there has been an increase in the level of co-prescribing of opioids and benzodiazepines and this has led to an increase in adverse outcomes.
American Medical Association Opioid Task Force. In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing naloxone with opioid pain medications when it is clinically appropriate to do so.
The Task Force indicated that physicians should consider:
- Whether the patient is on a high opioid dose,
- Whether the patient is on a benzodiazepine prescription,
- Whether the patient has a history of substance abuse disorder,
- Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose,
- Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose,
6) Whether the patient may be in a position to aid someone at risk of an overdose.
ARGUMENTS IN SUPPORT:
The California Pharmacists Association writes in support, stating that "naloxone only saves lives when people have the medication in their possession prior to someone experiencing an overdose. Use of naloxone ensures that a person experiencing an opioid overdose lives long enough for emergency medical care to arrive.… Requiring co-prescribing of this drug seems a reasonable and measured approach."
The County Health Executives Association of California writes in support, stating "[this bill] is a harm-reduction strategy that seeks to ensure this life-saving reversal tool is accessible for those that may be of higher risk of overdosing."
The Drug Policy Alliance writes in support that this bill is consistent "with the consensus that naloxone co-prescription is a safe and rational response to the overdose crisis in the United States."
ARGUMENTS IN OPPOSITION:
The California Medical Association writes in opposition, stating that "mandating that a specific medication be prescribed in a variety of situations, regardless of the individual patient characteristics, is inappropriate and places the government between a patient and his or her physician."
Analysis Prepared by: Robert Sumner / B. & P. / (916) 319-3301 FN: 0002951
Date of Hearing: May 16, 2018
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez Fletcher, Chair
ABPCA Bill Id:AB 2760
Author:(Wood) – As Amended Ver:April 19, 2018
Policy Committee: | Business and Professions | Vote: | 14 - 1 |
Health | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill requires a prescriber to educate patients, their parents, or any person the patients designate about naloxone hydrochloride or another opioid antagonist. The bill also requires a prescriber to offer a prescription for such a drug, if a patient meets specified clinical or risk-based criteria.
It also makes a failure to do either of the preceding actions unprofessional conduct and grounds for disciplinary action by the prescriber's licensing board.
FISCAL EFFECT:
- Uncertain potential costs to the Medi-Cal program. Medi-Cal would likely incur higher costs to reimburse for additional naloxone hydrochloride or other opioid antagonists, which may be offset by fewer health care services related to overdose (GF/federal).
- Ongoing enforcement costs to the Medical Board of California and the Board of Pharmacy will likely increase, but the extent of the increase is unknown.
COMMENTS:
- Purpose. Requiring the co-prescribing of naloxone, an opioid antagonist, for patients at high-risk of overdose places an immediate deterrent into the hands of those directly impacted or into the hands of their family, caregivers and friends.
- Background. Most opioid analgesics (pain relief drugs) are Schedule II drugs—drugs with a recognized medical use, but with a high potential for abuse, that may lead to severe psychological or physical dependence. A number of prescribing guidelines exist, but adoption is not universal among health care providers. Over 2,000 people died due to opioid overdoes in California in 2016. This bill appears consistent with federal expert recommendations.
- Related Legislation. AB 1998 (Rodriguez), currently pending on the Suspense File of this committee, requires health care practitioners authorized to prescribe specified opioid drugs to adopt a safe prescribing protocol. The bill also establishes an unspecified goal for a percentage reduction in opiate prescriptions that must be monitored and reported on by the California Department of Public Health (CDPH) by January 1, 2022.
- Support. The County Health Executives Association of California states the American Medical Association Opioid Task Force last year encouraged physicians to co-prescribe naloxone when it is clinically appropriate to do so. Drug Policy Alliance states naloxone co-prescription is an important component of a larger strategy to end overdose mortality, along with increasing access to evidence-based harm reduction and drug treatment strategies. The National Health Law Program and the California Pharmacists Association also support this bill.
- Opposition. The California Medical Association and the California Academy of Family Physicians oppose this bill, arguing it is inappropriate to mandate a specific medication be prescribed and that it removes physician discretion.
- Staff Comment. This bill specifies an opioid dosage of 90 morphine milligrams or more per day an offer of an opioid antagonist. A dosage level may be too specific to be enshrined in statute. Because medical science and recommendations may change, the author may wish to avoid referencing specific dosages and medications in favor of more general requirements, or allow for a reevaluation should evidence-based recommendations change.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: April 17, 2018
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 2760
Author:(Wood) – As Amended Ver:April 3, 2018
SUBJECT: Prescription drugs: naloxone hydrochloride.
SUMMARY: Requires a prescriber, as defined, to prescribe naloxone hydrochloride (naloxone) for a patient identified to be in an identified risk group. Requires a prescriber to provide education to patients receiving a naloxone prescription and to their households on overdose prevention and use of naloxone. Specifically, this bill:
- Defines a prescriber to mean a person licensed, certified, registered or otherwise subject to regulation who is authorized to prescribe prescription drugs.
- Requires a prescriber to prescribe naloxone for a patient when one or more of the following conditions are present:
- The prescription dosage for the patient is 90 or more morphine milligram equivalents (mme) of an opioid medication per day;
- An opioid medication is prescribed concurrently with a prescription for benzodiazepine; and,
- The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder (SUD), or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
- Requires a prescriber to provide education to patients receiving a prescription under 2) above and their households on overdose prevention and use of naloxone.
- Makes a violation of this bill unprofessional conduct and grounds for disciplinary action by the prescriber’s licensing board.
- Requires each licensing board to enforce this bill as it pertains to the respective board’s prescribers.
- Makes several findings and declarations related to the on-going opioid epidemic.
EXISTING LAW:
- Provides for the licensure, registration, certification, regulation, and oversight of various prescribing healthcare providers through licensing boards including the Medical Board of California (MBC), the Board of Pharmacy (BOP), the Dental Board of California, and others.
- Authorizes licensed pharmacists to furnish naloxone (without a prescription) in accordance with protocols developed and approved jointly by the BOP and the MBC.
- Authorizes healthcare providers such as physicians and surgeons, dentists, nurse practitioners, and osteopathic doctors, who are licensed to prescribe an opioid antagonist to prescribe and subsequently dispense or distribute an opioid antagonist to either a person at risk or to a family member, friend or other person in a position to assist a person at risk of an opioid overdose.
FISCAL EFFECT: This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, California and the nation are experiencing an opioid epidemic. California ranks in the top five states when it comes to the raw number of drug-overdose deaths. While efforts aimed at stemming the opioid crisis appear to be making inroads, the sheer number and potential for ever-increasing numbers requires action. Requiring the co-prescribing of naloxone, an opioid antagonist, for patients at high-rise of overdose places an immediate deterrent into the hands of those directly impacted or into the hands of their family, caregivers and friends. The author states, co-prescribing naloxone to individuals who meet certain risk categories will help to stem the rising number of drug overdose deaths in California.
- BACKGROUND.
Opioids. Opioids are a class of narcotic drugs that include medications such as hydrocodone, oxycodone, morphine, codeine, and other related drugs. Most opioid analgesics are classified at Schedule II drugs in the California Uniform Controlled Substances Act (CUCSA), in that they have a recognized medical use, but also have a high potential for abuse that may lead to severe psychological and/or physical dependence. According to the Department of Public Health (DPH), in the past prescription opioids were prescribed for relieving short-term (acute) pain. Today, they are increasingly being used for long-term (chronic) pain management. As a result, sales of opioid pain relievers have quadrupled in the past 10 years. Taken as prescribed, opioids can be used to manage pain safely and effectively. However, opioids may also produce other effects including euphoric response since these drugs affect the regions of the brain involving reward response. The National Institute on Drug Abuse states that those who abuse opioids may seek to intensify their experience by taking the drug in ways other than those prescribed such as snorting or injecting, thereby increasing their risk for serious medical complications, including overdose. Prescription opioid misuse can lead to long-term health problems, trouble breathing, overdose. and death.
The opioid crisis has been declared a public health emergency by the White House in that nationally the opioid crisis is credited with the deaths of more than 50,000 Americans in 2016. In 2016 DPH reported 2,031 opioid deaths in California with 4,623 emergency department (ED) visits for all opioids (excluding heroin). In 2016, deaths as a result of Fentanyl increased to 237 and there were more than 23.6 million opioid prescriptions issued in the State of California.
- Benzodiazepines. Benzodiazepines are depressants that produce sedation, induce sleep, relieve anxiety and muscle spasms, and prevent seizures. Taken in combination with drugs that suppress central nervous system depressants, such as opioids, the risk of overdose increases dramatically. The risk of overdose death goes up nearly fourfold when benzodiazepines are combined with opioids, yet rates of co-prescribing benzodiazepines and opioids nearly doubled between 2001 and 2013. Overdose deaths involving benzodiazepines increased more than sevenfold between 1999 and 2015.
- Naloxone. Naloxone is an opioid antagonist that acts immediately to block the effects of opioids on the central nervous system, stopping the effects of an opioid overdose. Naloxone is currently a prescription drug, but is not a controlled substance. It has few known adverse effects, no potential for abuse, and can be rapidly administered through intramuscular injection or nasal spray (Narcan). When administered quickly and appropriately, naloxone can prevent drug overdose deaths. Currently it is common practice for emergency departments and emergency first responders to administer naloxone when encountering a drug overdose.
While most professional first responders and EDs are equipped with naloxone, emergency service providers may not arrive in time to revive overdose victims. Trained and equipped bystanders such as friends, family, and other non-health care providers (lay people) and drug users themselves can effectively respond and reverse an opioid overdose. Given the success of bystander naloxone programs, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommended expanding the availability of naloxone to lay people.
- Prescribers. California allows for several categories of healthcare providers to prescribe drugs listed in the CUCSA. Among healthcare providers authorized to prescribe narcotics are: physicians and surgeons, dentists, veterinarians, osteopathic doctors, optometrists, and podiatrists. Naturopathic doctors may prescribe drugs contained in Schedules III-V of the CUCSA under the supervision of a physician and surgeon and in compliance with a protocol developed jointly by the physician and surgeon and the naturopathic doctor. Additionally, nurse practitioners, certified nurse midwives, and physician assistants are authorized to prescribe drugs contained in Schedules II-V of the CUSCA under the supervision of a physician and surgeon and in compliance with protocols developed jointly by the physician and surgeon and the nurse practitioners, certified nurse midwife, or physician assistant.
- Existing Opioid Prescribing Guidelines. The incorporation or co-prescription of naloxone when prescribing opioids for patients in identified risk groups is widely accepted by medical and addiction treatment organizations including the WHO, and the Centers for Medicare & Medicaid Services, the American Society of Addiction Medicine. Two examples of recommendations are included below.
- CDC. The CDC Guidelines for Prescribing Opioids for Chronic Pain, March 2016, state in part that:
“Most experts agree that clinicians should consider offering naloxone when prescribing opioids to patients at increased risk for overdose, including patients with a history of overdose, patients with a history of SUD, patients taking benzodiazepines with opioids, patients at risk for returning to a high dose to which they are no longer tolerant, and patients taking higher dosages of opioids (more than 50 mme/day). Practices should provide education on overdose prevention and naloxone use to patients receiving naloxone prescriptions and to members of their households.”
- American Medical Association (AMA) Opioid Task Force. The AMA Opioid Task Force of 2017 encourages physicians to consider co-prescribing naloxone when it is clinically appropriate to do so. It lists six factors to consider when determining whether to co-prescribe naloxone to a patient, or to a family member or close friend of the patient. These factors include:
- Does the patient history or prescription drug monitoring program show the patient is on a high opioid dose;
- Is the patient also on a concomitant benzodiazepine prescription;
- Does the patient have a history of substance use disorder;
- Does the patient have an underlying mental health condition that might make him or her more susceptible to overdose;
- Does the patient have a medical condition, such as a respiratory disease, sleep apnea or other comorbidities, which might make him or her susceptible to opioid toxicity, respiratory distress or overdose; and,
- Might the patient be in a position to aid someone who is at risk of opioid overdose.
- American Medical Association (AMA) Opioid Task Force. The AMA Opioid Task Force of 2017 encourages physicians to consider co-prescribing naloxone when it is clinically appropriate to do so. It lists six factors to consider when determining whether to co-prescribe naloxone to a patient, or to a family member or close friend of the patient. These factors include:
- U.S. Surgeon General National Advisory (Advisory). In the first national advisory issued by a Surgeon General since 2005, U.S. Surgeon General Dr. Jerome M. Adams, issued a national advisory on April 5, 2018, urging more Americans to keep on hand and learn to use Naloxone. In the advisory he stated: “For patients currently taking high doses of opioids as prescribed for pain, individuals misusing prescriptions opioids, individuals using illicit opioids such as heroin or fentanyl, health care practitioners, family and friends of people who have an opioid use disorder, and community members who come into contact with people at risk for opioid overdose, knowing how to use naloxone and keeping it within reach can save a life.”
- DPH Naloxone Grant Program. SB 833 (Committee on Budget and Fiscal Review), Chapter 30, Statutes of 2016, established a new Naloxone Grant Program within DPH with the goal of reducing the number of fatal overdoses in California from opioid drugs, including prescription opioids and heroin, by increasing access to the life-saving drug naloxone. A total of $3 million was allocated on a one-time basis to support this program. In March 27, 2017, DPH began offering grants of naloxone product (Narcan nasal spray) and funding to all 61 local health departments (LHDs) to conduct Naloxone Distribution Projects. LHDs provide Narcan to local programs, agencies and community-based organizations within their jurisdictions that have naloxone distribution systems and are in the best position to save lives from opioid overdose.
- SUPPORT. The County Health Executives Association of California (CHEAC) states that the AMA Opioid Task Force last year encouraged physicians to co-prescribe naloxone when it is clinically appropriate to do so, including when a patient is prescribed benzodiazepines or when a patient has a history of SUD. CHEAC states that this bill is a harm-reduction strategy that seeks to ensure that a life-saving, reversal tool is accessible to those that may be at a higher risk of overdosing.
The National Health Law Program states that this bill would ensure that those who are prescribed opioids and are at risk for an opioid-related overdose receive the over-dose reversing medication naloxone. In so doing, the bill will help save the lives of many Californians with opioid use disorders.
The Drug Policy Alliance states in support of the bill that the need for the bill is urgent: accidental drug overdose is the leading cause of accidental death in the U.S. having risen astronomically in the last decade. Naloxone co-prescription is an important component of a larger strategy to end overdose mortality, along with increasing access to evidence-based harm reduction and drug treatment strategies.
- OPPOSITION. The California Medical Association (CMA) states that mandating a specific medication be prescribed in a variety of situations, regardless of the individual patient characteristics, is inappropriate and places the government between a patient and their physicians. CMA further states that this bill seeks to remove physician discretion in treatment planning with a patient. Additionally, the California Academy of Family Physicians states that even though physicians already consider each risk factor and potential drug interaction before prescribing medication, this bill disrupts this process and removes the physician’s ability to determine the most appropriate treatment plan for their patient.
- RELATED LEGISLATION.
- AB 1963 (Waldron) increases Medi-Cal reimbursement rates for providers who prescribe medication assisted drug treatments. AB 1963 is pending in the Assembly Appropriations Committee.
- AB 1998 (Rodriguez) requires every health care practitioner authorized to prescribe opioids to adopt a safe prescribing protocol by June 1, 2019, as specified. AB 1998 is pending in the Assembly Health Committee.
- AB 2086 (Gallagher) allows prescribers of controlled substances to access the Controlled Substances Utilization Review and Evaluation System (CURES) database and review a list of patients for whom the prescriber is listed as being the prescriber. AB 2086 is pending in the Assembly Appropriations Committee.
- AB 2256 (Santiago) authorizes a pharmacy or wholesaler to furnish naloxone hydrochloride or other opioid antagonists to law enforcement agencies, under specified conditions. AB 2256 is pending in the Assembly Public Safety Committee.
- AB 2384 (Arambula) requires that drug formularies maintained by healthcare service plans, including Medi-Cal, or health insurers include specified prescription drugs for medication assisted treatment (MAT) and provides that MAT is presumed to be medically necessary and not subject to specified requirements including prior authorization and an annual or lifetime dollar limit. AB 2384 is pending in the Assembly Health Committee.
- AB 2741 (Burke) limits all opioid prescriptions for minors to a maximum of five days and requires a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain written consent prior to writing the prescription. AB 2741 is pending in the Assembly Health Committee.
- AB 2783 (O’Donnell) reclassifies specified hydrocodone combination products as Schedule II controlled substances. AB 2783 is pending in the Assembly Public Safety Committee.
- AB 2789 (Wood) requires that by January 1, 2020 health care practitioners authorized to issue prescriptions have the capability to transmit electronic data transmission prescriptions and requires that by January 1, 2021, health care practitioners issue prescriptions as an electronic data transmission. AB 2789 is pending in the Assembly Appropriations Committee.
- PREVIOUS LEGISLATION.
- AB 1748 (Mayes), Chapter 557, Statutes of 2016, authorized school nurses and other trained personnel to use naloxone or another opioid antagonist to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an opioid overdose, and authorized pharmacies to furnish naloxone, without a prescription, to a school district, county office of education, or charter school.
- AB 1535 (Bloom), Chapter 326, Statutes of 2014, authorized pharmacists to furnish naloxone without a prescription, pursuant to standardized procedures developed by the BOP and the MBC.
- AUTHOR'S AMENDMENTS. The author proposes to amend this bill as follows:
- Limit the bill by requiring an offer of a prescription rather than a requirement to prescribe.
(a) Offer a prescription Prescribe for naloxone hydrochloride or other opioid antagonist for to a patient when one or more of the following conditions are present:
b) Clarify his intent on providing education to patients and other persons.
(b) Provide education to patients receiving a prescription under subdivision (a). and their households on overdose prevention and the use of naloxone hydrochloride or other opioid antagonist. Provide education on overdose prevention and the use of naloxone hydrochloride or other opioid antagonist to another person or persons designated by the patient or for a minor their parent or guardian.
REGISTERED SUPPORT / OPPOSITION:
Support
California Pharmacists Association
County Health Executives Association of California
Drug Policy Alliance
National Health Law Program
Opposition
California Academy of Family Physicians
California Medical Association
Analysis Prepared by: Judith Babcock / HEALTH / (916) 319-2097
Date of Hearing: April 10, 2018
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 2760
Author:(Wood) – As Amended Ver:April 3, 2018
NOTE: This bill is double-referred and if passed by this committee it will be referred to the Assembly Committee on Health.
SUBJECT: Prescription drugs: naloxone hydrochloride.
SUMMARY: This bill would require a prescriber to prescribe naloxone hydrochloride for patients when certain conditions are present and to provide specified education to those patients and their households.
EXISTING LAW:
- Establishes the Medical Board of California to license and regulate the practice of medicine and authorizes physicians and surgeons to prescribe medications. (Business and Professions Code Section 2000 et seq)
- Establishes the Dental Board of California to license and regulate the practice of dentistry and authorizes dentists to prescribe medications. (Business and Professions Code Section 1600 et seq)
- Establishes the Veterinary Medical Board of California to license and regulate the practice of veterinary medicine and authorizes veterinarians to prescribe medications. (Business and Professions Code Section 4800 et seq)
- Establishes the Board of Registered Nursing to license and regulate the practice of nursing and authorizes nurse practitioners and certified nurse midwives, under certain circumstances, to prescribe medications. (Business and Professions Code Section 2700 et seq)
- Establishes the Physician Assistant Board to license and regulate the practice of physician assistants and authorizes physician assistants, under certain circumstances, to prescribe medications. (Business and Professions Code Section 3500 et seq)
- Establishes the Osteopathic Medical Board of California to license and regulate the practice of osteopathic medicine and authorizes osteopathic doctors to prescribe medications. (Business and Professions Code Section 3600 et seq)
- Establishes the Naturopathic Medicine Committee within the Osteopathic Board of California to license and regulate the practice of naturopathic medicine and authorizes naturopathic doctors to prescribe medications. (Business and Professions Code Section 3610 et seq)
- Establishes the State Board of Optometry to license and regulate the practice of optometry and authorizes optometrists to prescribe medications. (Business and Professions Code Section 3000 et seq)
- Establishes the California Board of Podiatric Medicine to license and regulate the practice of podiatric medicine and authorizes podiatric doctors to prescribe medications. (Business and Professions Code Section 2460 et seq)
- Authorizes a pharmacist to furnish naloxone hydrochloride (without a prescription) in accordance with standardized procedures or protocols developed and approved by the Board of Pharmacy and the Medical Board of California. (Business and Professions Code Section 4052.01)
- Authorizes a licensed health care provider who is authorized by law to prescribe an opioid antagonist to prescribe and subsequently dispense or distribute an opioid antagonist to a person at risk of an opioid-related overdose or to a family member, friend, or other person in a position to assist a person at risk of an opioid-related overdose. (Civil Code Section 1714.22)
THIS BILL:
- Makes findings and declarations.
- Defines “prescriber” to mean a person licensed, certified, registered, or otherwise subject to regulation who is authorized to prescribe prescription drugs.
- Notwithstanding any other law, requires a prescriber to:
- Prescribe naloxone hydrochloride for a patient when one or more of the following conditions are present:
- The prescription dosage for the patient is over 90 morphine milligram equivalents of an opioid medication per day.
- An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
- The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.
- Provide education to patients receiving a prescription under this bill and their households on overdose prevention and the use of naloxone hydrochloride.
- Prescribe naloxone hydrochloride for a patient when one or more of the following conditions are present:
- Makes a violation of the bill’s provisions unprofessional conduct and grounds for disciplinary action by the prescriber’s licensing board.
- Make each licensing board responsible for enforcing the requirements of the bill as it pertains to that board’s prescribers.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the author. According to the author, “while efforts aimed at stemming the opioid crisis appear to be making some inroads, the sheer number and potential for ever increasing numbers requires pro-active action on the part of the legislature. Requiring the co-prescribing of naloxone for those at high-risk places an immediate deterrent into the hands of those directly impacted or into the hands of their family and caregivers. It is a tool that can immediately save lives and hopefully provide an opportunity for discussion of treatment for individuals suffering from substance use disorder”.
Background. Overview of the Opioid Crisis. In October of 2017, the White House declared the opioid crisis a public health emergency, formally recognizing what had long been understood to be a growing epidemic responsible for devastation in communities across the country. According to the Centers for Disease Control and Prevention, as many as 50,000 Americans died of an opioid overdose in 2016, representing a 28 percent increase over the previous year. Additionally, the number of Americans who died of an overdose of fentanyl and other opioids more than doubled during that time with nearly 20,000 deaths. These death rates compare to, and potentially exceed, those at the height of the AIDS epidemic.
Opioids are a class of drugs prescribed and administered by health professionals to manage pain. Modern use of the term “opioid” typically describes both naturally occurring opiates derived from the opium poppy as well as their manufactured synthetics. Common examples of prescription opioids include oxycodone (OxyContin, Percocet); hydrocodone (Vicodin, Norco, Lorcet); codeine; morphine; and fentanyl. Heroin is also an opioid.
In addition to providing pain relief, opioids can be used as a cough suppressant, an antidiarrheal, a method of sedation, and a treatment for shortness of breath. The majority of pharmaceutical opioids are Schedule II drugs under the federal Controlled Substances Act, considered by the federal Drug Enforcement Agency (DEA) to have a high potential for abuse that may lead to severe psychological or physical dependence. However, combination drugs containing lower doses of opioids combined with other active ingredients are typically less restricted; for example, cough syrups containing low doses of codeine are frequently classified Schedule V medications.
The abuse of prescription drugs was historically viewed as a criminal concern analogous to street narcotics cases regularly investigated by law enforcement. In recent years, however, an expert consensus has evolved around the opinion that the opioid crisis must be addressed through the lens of public health policy. This belief is supported by research demonstrating how health professionals may have inadvertently contributed to the origins of the crisis. It is widely accepted that health professionals will play a necessarily critical role in any meaningful solutions.
In the opioid crisis’s broader national context, there has been a persistent perception that California represents a relatively minor segment of an epidemic more typically identified with states like New Hampshire and West Virginia. However, there is significant evidence that communities in California have been much harder hit than may be generally believed. For example, in 2015, several rural counties in California saw as many or more drug overdose deaths per 100,000 residents than some Midwestern states. It has been reported than some small counties had more opioid prescriptions than residents. In total, the California Department of Public Health estimates that nearly 2,000 Californians died of an opioid overdose in 2016.
In February of 2018, a bipartisan coalition of California State Assemblymembers announced a package of legislation aimed at combating the opioid crisis. The bills have been presented as representing a diversity of approaches to curbing overprescription, encouraging treatment, and preventing diversion. The potential of each proposed measure to effectively address the epidemic of prescription drug abuse must be evaluated in proportion to any added burden to those health professionals who remain tasked with ensuring that legitimate treatment continues to be provided to patients with pain management needs.
Naloxone hydrochloride and other opioid antagonists. Naloxone hydrochloride (brand name Narcan) is an opioid antagonist. This means that naloxone acts blocks the effects of opioids on the central nervous system, stopping the effects of an opioid overdose such as suppressed breathing. Naloxone can be administered through an intravenous injection, through an intermuscular injection, or via a nasal spray. Naloxone was approved by the federal Food and Drug Administration for the treatment of opioid overdose in 1971 and is available as a generic medication. Because naloxone is simple to administer and does not pose significant risk to the patient, it can be used by lay people with minimal instruction. Current law allows a prescriber to prescribe naloxone to an individual at risk of an opioid overdose or to a family member, friend, or other person in a position to assist an individual who is at risk of an opioid overdose. Current law also allows a pharmacist to dispense naloxone, without a prescription, provided standard protocols are followed.
Benzodiazepines and opioid risks. Benzodiazepines are a class of drugs used to treat anxiety, insomnia, agitation, seizures, muscle spasms, and alcohol withdrawal. When taken in combination with drugs that suppress central nervous system depressants, such as opioids, the risk of fatal overdose increases. According to the Food and Drug Administration, there has been an increase in the level of co-prescribing of opioids and benzodiazepines and this has led to an increase in adverse outcomes.
American Medical Association Opioid Task Force. In August 2017, the American Medical Association Opioid Task Force encouraged physicians to consider co-prescribing naloxone with opioid pain medications when it is clinically appropriate to do so.
The Task Force indicated that physicians should consider:
1) Whether the patient is on a high opioid dose,
2) Whether the patient is on a benzodiazepine prescription,
3) Whether the patient has a history of substance abuse disorder,
4) Whether the patient has an underlying mental health condition that may make the patient more susceptible to overdose,
5) Whether the patient has a medical condition which might make the patient more susceptible to opioid toxicity, respiratory distress, or overdose,
6) Whether the patient may be in a position to aid someone at risk of an overdose.
Current Related Legislation.
AB 1751 (Low) would provide a framework for the CURES PDMP to connect with other states that comply with California’s patient privacy and data security standards. This bill will be heard in this committee on April 10th.
AB 1752 (Low) would add Schedule V drugs to the CURES database and change the requirement for pharmacists to report dispensed prescriptions from seven days to the following business day. This bill will be heard in this committee on April 10th.
AB 1753 (Low) would limit the number of security printers authorized to manufacture prescription pads and linking uniquely serialized pads with CURES. This bill will be heard in this committee on April 10th.
AB 1963 (Waldron) would incentivize medical providers to become certified prescribers of medication-assisted treatment by increasing the reimbursement rates for providers who prescribe these drug treatments. This bill is pending in the Assembly Health Committee.
AB 2086 (Gallagher) would allow prescribers of controlled substances to review a list of patients for whom they are listed as being the prescriber. This bill will be heard in this committee on April 10th.
AB 2256 (Santiago) would authorize a pharmacy or wholesaler to furnish naloxone hydrochloride or other opioid antagonists to law enforcement agencies, under specified conditions. This bill will be heard in this committee on April 10th.
AB 2384 (Arambula) would remove barriers to medication-assisted treatment, such as prior authorization requirements and limits on coverage. This bill is pending in the Assembly Health Committee.
AB 2486 (McCarty) would establish the Opioid Prevention and Rehabilitation Program Fund to treat opioid addiction by providing existing programs the additional funding. This bill is pending in the Assembly Health Committee.
AB 2487 (McCarty) would add opioid addiction training as a continuing medical education requirement for certain physicians in order to increase the availability of buprenorphine treatment. This bill will be heard in this committee on April 10th.
AB 2741 (Burke) would limit all opioid prescriptions for minors to a maximum of 5 days, with exceptions, and require a prescriber to discuss risks related to opioid medication with the minor and the minor’s parent or guardian and obtain written consent prior to writing the prescription. This bill will be heard in this committee on April 10th.
AB 2783 (O’Donnell) would reconcile discrepancies between California’s controlled substance schedules and the corresponding federal controlled substance schedules. This bill is pending in the Assembly Public Safety Committee.
AB 2789 (Wood) would require that prescriptions be submitted electronically, with limited exceptions. This bill will be heard in this committee on April 10th.
AB 2859 (Caballero) would increase safe storage practices among parents to prevent access to prescription drugs in the home by children and adolescents. This bill will be heard in this committee on April 10th.
Prior Related Legislation.
AB 1748 (Mayes), Chapter 557, Statutes of 2016, authorizes school nurses and other trained personnel to use naloxone hydrochloride (naloxone) or another opioid antagonist to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an opioid overdose. That bill also authorizes pharmacies to furnish naloxone, without a prescription, to a school district, county office of education, or charter school.
AB 1535 (Bloom), Chapter 326, Statutes of 2014, authorizes pharmacists to furnish naloxone without a prescription, pursuant to standardized procedures developed by the Board of Pharmacy and the Medical Board of California.
ARGUMENTS IN SUPPORT:
The California Pharmacists Association writes in support, stating “Naloxone only saves lives when people have the medication in their possession prior to someone experiencing an overdose. Use of naloxone ensures that a person experiencing an opioid overdose lives long enough for emergency medical care to arrive…Requiring co-prescribing of this drug seems a reasonable and measured approach…”.
The County Health Executives Association of California writes in support, stating “[this bill] is a harm-reduction strategy that seeks to ensure this life-saving reversal tool is accessible for those that may be of higher risk of overdosing”.
The Drug Policy Alliance writes in support that this bill is consistent “with the consensus that naloxone co-prescription is a safe and rational response to the overdose crisis in the United States…”.
ARGUMENTS IN OPPOSITION:
The California Medical Association writes in opposition, stating that “mandating that a specific medication be prescribed in a variety of situations, regardless of the individual patient characteristics, is inappropriate and places the government between a patient and his or her physician”.
POLICY ISSUE(S) FOR CONSIDERATION:
The bill requires prescribers to both prescribe naloxone and to provide education to patients and their households on overdose prevention when certain conditions are met. Because not all prescribers may have a clinical relationship with their patients’ families, the author may consider providing more flexibility to prescribers when meeting this requirement.
REGISTERED SUPPORT:
California Pharmacists Association
County Health Executives Association
Drug Policy Alliance
REGISTERED OPPOSITION:
California Medical Association
Analysis Prepared by: Brendan McCarthy / B. & P. / (916) 319-3301
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Business, Professions and Economic Development
Assembly Floor
Assembly Standing Committee on Appropriations
Assembly Standing Committee on Health
Assembly Standing Committee on Business and Professions
Bill Author
Bill Co-Author(s):